These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8930005)

  • 1. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine.
    Haddjeri N; Blier P; de Montigny C
    Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():11-7. PubMed ID: 8930005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission.
    Haddjeri N; Blier P; de Montigny C
    J Affect Disord; 1998 Dec; 51(3):255-66. PubMed ID: 10333981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.
    de Boer T
    Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():19-23. PubMed ID: 8930006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of rapid-onset antidepressant treatment strategies.
    Blier P
    J Clin Psychiatry; 2001; 62 Suppl 15():12-7. PubMed ID: 11444761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission.
    Haddjeri N; Blier P; de Montigny C
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):20-9. PubMed ID: 9007838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
    Millan MJ; Gobert A; Rivet JM; Adhumeau-Auclair A; Cussac D; Newman-Tancredi A; Dekeyne A; Nicolas JP; Lejeune F
    Eur J Neurosci; 2000 Mar; 12(3):1079-95. PubMed ID: 10762339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo.
    Bengtsson HJ; Kele J; Johansson J; Hjorth S
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Nov; 362(4-5):406-12. PubMed ID: 11111835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of mirtazapine in clinically relevant subgroups of depressed patients.
    Nutt DJ
    Depress Anxiety; 1998; 7 Suppl 1():7-10. PubMed ID: 9597345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacologic profile of mirtazapine.
    de Boer T
    J Clin Psychiatry; 1996; 57 Suppl 4():19-25. PubMed ID: 8636062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of antidepressants: selectivity or multiplicity?
    Westenberg HG
    J Clin Psychiatry; 1999; 60 Suppl 17():4-8; discussion 46-8. PubMed ID: 10446734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain.
    Haddjeri N; Blier P; de Montigny C
    J Pharmacol Exp Ther; 1996 May; 277(2):861-71. PubMed ID: 8627568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirtazapine: clinical overview.
    Gorman JM
    J Clin Psychiatry; 1999; 60 Suppl 17():9-13; discussion 46-8. PubMed ID: 10446735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirtazapine augmentation in the treatment of refractory depression.
    Carpenter LL; Jocic Z; Hall JM; Rasmussen SA; Price LH
    J Clin Psychiatry; 1999 Jan; 60(1):45-9. PubMed ID: 10074878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
    Fawcett J; Barkin RL
    J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects.
    Stimmel GL; Dopheide JA; Stahl SM
    Pharmacotherapy; 1997; 17(1):10-21. PubMed ID: 9017762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain.
    Besson A; Haddjeri N; Blier P; de Montigny C
    Eur Neuropsychopharmacol; 2000 May; 10(3):177-88. PubMed ID: 10793320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction?
    Dinan TG
    J Clin Psychiatry; 1996; 57 Suppl 4():14-8. PubMed ID: 8636061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan.
    de Boer TH; Nefkens F; van Helvoirt A; van Delft AM
    J Pharmacol Exp Ther; 1996 May; 277(2):852-60. PubMed ID: 8627567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo.
    De Boer T; Nefkens F; Van Helvoirt A
    Eur J Pharmacol; 1994 Feb; 253(1-2):R5-6. PubMed ID: 7912194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.